Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Which interventions offer best value for money in primary prevention of cardiovascular disease?

Cobiac LJ, Magnus A, Lim S, Barendregt JJ, Carter R, Vos T.

PLoS One. 2012;7(7):e41842. doi: 10.1371/journal.pone.0041842. Epub 2012 Jul 23.

2.

Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study.

Cobiac LJ, Magnus A, Barendregt JJ, Carter R, Vos T.

BMC Public Health. 2012 Jun 1;12:398. doi: 10.1186/1471-2458-12-398.

5.
7.

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.

8.

Choice of generic antihypertensive drugs for the primary prevention of cardiovascular disease--a cost-effectiveness analysis.

Wisløff T, Selmer RM, Halvorsen S, Fretheim A, Norheim OF, Kristiansen IS.

BMC Cardiovasc Disord. 2012 Apr 4;12:26. doi: 10.1186/1471-2261-12-26.

9.
10.

The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?

Grover SA, Ho V, Lavoie F, Coupal L, Zowall H, Pilote L.

Arch Intern Med. 2003 Feb 10;163(3):333-9.

PMID:
12578514
11.

Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.

Greving JP, Buskens E, Koffijberg H, Algra A.

Circulation. 2008 Jun 3;117(22):2875-83. doi: 10.1161/CIRCULATIONAHA.107.735340. Epub 2008 May 27.

12.

Primary prevention of cardiovascular disease: cost-effectiveness comparison.

Franco OH, der Kinderen AJ, De Laet C, Peeters A, Bonneux L.

Int J Technol Assess Health Care. 2007 Winter;23(1):71-9.

PMID:
17234019
13.

The cost-effectiveness of exercise training for the primary and secondary prevention of cardiovascular disease.

Lowensteyn I, Coupal L, Zowall H, Grover SA.

J Cardiopulm Rehabil. 2000 May-Jun;20(3):147-55.

PMID:
10860196
14.

The impact of prevention on reducing the burden of cardiovascular disease.

Kahn R, Robertson RM, Smith R, Eddy D.

Circulation. 2008 Jul 29;118(5):576-85. doi: 10.1161/CIRCULATIONAHA.108.190186. Epub 2008 Jul 7.

15.

Effectiveness of programmes as part of primary prevention demonstrated on the example of cardiovascular diseases and the metabolic syndrome.

Korczak D, Dietl M, Steinhauser G.

GMS Health Technol Assess. 2011 Apr 1;7:Doc02. doi: 10.3205/hta000093.

16.

A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.

Tsutani K, Igarashi A, Fujikawa K, Evers T, Kubin M, Lamotte M, Annemans L.

Intern Med. 2007;46(4):157-62. Epub 2007 Feb 15.

17.
18.

Prevention of cardiovascular events in elderly people.

Andrawes WF, Bussy C, Belmin J.

Drugs Aging. 2005;22(10):859-76. Review.

PMID:
16245959
19.

Cost effectiveness and equity of a community based cardiovascular disease prevention programme in Norsjö, Sweden.

Lindholm L, Rosén M, Weinehall L, Asplund K.

J Epidemiol Community Health. 1996 Apr;50(2):190-5.

20.

[Cardiovascular risk and cardiometabolic risk: an epidemiological evaluation].

Vanuzzo D, Pilotto L, Mirolo R, Pirelli S.

G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):6S-17S. Review. Italian.

PMID:
18773746

Supplemental Content

Support Center